$3.23
6.79%
Nasdaq, Sep 19, 10:14 pm CET
ISIN
US76029N1063
Symbol
REPL

Replimune Group, Inc. Stock price

$3.23
-2.06 38.92% 1M
-8.28 71.96% 6M
-8.89 73.37% YTD
-8.01 71.28% 1Y
-13.06 80.19% 3Y
-19.45 85.77% 5Y
-11.94 78.73% 10Y
-11.94 78.73% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
-0.24 6.79%
ISIN
US76029N1063
Symbol
REPL
Industry

Key metrics

Basic
Market capitalization
$251.7m
Enterprise Value
$-79.5m
Net debt
positive
Cash
$403.3m
Shares outstanding
77.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.8
Financial Health
Equity Ratio
75.4%
Return on Equity
-59.5%
ROCE
-71.9%
ROIC
-644.4%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-292.3m | $-211.1m
EBIT
$-294.7m | $-301.9m
Net Income
$-280.2m | $-263.3m
Free Cash Flow
$-227.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-24.9% | 18.5%
EBIT
-24.6% | -15.4%
Net Income
-27.4% | -6.5%
Free Cash Flow
-18.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.1
FCF per Share
$-2.9
Short interest
44.7%
Employees
331
Rev per Employee
$0.0
Show more

Is Replimune Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Replimune Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

7x Buy
47%
7x Hold
47%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

Buy
47%
Hold
47%
Sell
7%

Financial data from Replimune Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 91 91
55% 55%
-
- Research and Development Expense 201 201
15% 15%
-
-292 -292
25% 25%
-
- Depreciation and Amortization 2.43 2.43
0% 0%
-
EBIT (Operating Income) EBIT -295 -295
25% 25%
-
Net Profit -280 -280
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Replimune Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Replimune Group, Inc. Stock News

Neutral
PRNewsWire
about 4 hours ago
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
Negative
The Motley Fool
3 days ago
One day after enduring a nearly 40% decline in its share price, bitoech Replimune (REPL -6.79%) was also down on Friday, although nowhere near as steeply. The company's stock was in the red by almost 7%, which didn't look so hot next to the S&P 500's (^GSPC 0.49%) gain of 0.5%.
More Replimune Group, Inc. News

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Head office United States
CEO Sushil Patel
Employees 331
Founded 2015
Website www.replimune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today